Oppenheimer upgraded shares of Crispr Therapeutics (NASDAQ:CRSP) from a market perform rating to an outperform rating in a report issued on Tuesday, Briefing.com Automated Import reports. They currently have $65.00 price target on the stock. Oppenheimer also issued estimates for Crispr Therapeutics’ Q1 2020 earnings at ($0.87) EPS, Q2 2020 earnings at ($0.95) EPS, Q3 2020 earnings at ($1.29) EPS, Q4 2020 earnings at ($1.38) EPS, FY2021 earnings at ($4.29) EPS, FY2022 earnings at ($4.70) EPS and FY2023 earnings at ($1.07) EPS.
CRSP has been the subject of a number of other reports. Jefferies Financial Group began coverage on shares of Crispr Therapeutics in a report on Thursday, August 1st. They set a buy rating and a $64.00 price objective for the company. Piper Jaffray Companies reaffirmed an overweight rating on shares of Crispr Therapeutics in a report on Monday, October 21st. BidaskClub raised shares of Crispr Therapeutics from a sell rating to a hold rating in a report on Thursday, October 31st. Zacks Investment Research downgraded shares of Crispr Therapeutics from a hold rating to a sell rating in a report on Monday, September 30th. Finally, ValuEngine raised shares of Crispr Therapeutics from a sell rating to a hold rating in a report on Friday, November 1st. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $57.95.
Shares of NASDAQ:CRSP traded up $1.81 during mid-day trading on Tuesday, reaching $56.87. The company had a trading volume of 763,200 shares, compared to its average volume of 749,333. The company’s 50-day moving average price is $43.31 and its 200-day moving average price is $44.57. The firm has a market cap of $3.04 billion, a price-to-earnings ratio of -16.53 and a beta of 3.15. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. Crispr Therapeutics has a one year low of $22.22 and a one year high of $57.40.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The company had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. On average, research analysts anticipate that Crispr Therapeutics will post 0.64 EPS for the current fiscal year.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at $412,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 21.40% of the company’s stock.
Institutional investors have recently bought and sold shares of the business. BSW Wealth Partners bought a new stake in Crispr Therapeutics in the second quarter worth $39,000. Balyasny Asset Management LLC bought a new stake in Crispr Therapeutics in the second quarter worth $5,165,000. BNP Paribas Arbitrage SA bought a new stake in Crispr Therapeutics in the second quarter worth $41,000. Bank of New York Mellon Corp raised its stake in shares of Crispr Therapeutics by 116.5% during the second quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock valued at $1,559,000 after acquiring an additional 17,810 shares during the last quarter. Finally, ARK Investment Management LLC raised its stake in shares of Crispr Therapeutics by 34.7% during the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after acquiring an additional 701,332 shares during the last quarter. 51.09% of the stock is owned by institutional investors and hedge funds.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: What is channel trading?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.